| |
|
|
| |
W e l c o m e |
|
| |
| |
|
| |
Dr. Ranjan Duara, MD |
Welcome from Dr. Duara
These annual Symposia on Mild Cognitive Impairment (MCI) and early Alzheimer's Disease were initiated in 2003 to address the increasing interest in understanding the earliest stages of various disorders that may ultimately lead to dementia. Even though Alzheimer's disease is the most frequent cause of dementia, many other conditions may accelerate its clinical progression or lead to dementia independently. Experts representing many different disciplines have contributed to the discussions at the MCI Symposia series and the feedback from the audience and the faculty in the last seven years has been very positive. We have every reason to believe that you will find the next meeting educational and intellectually stimulating. Please consider attending the Eighth Annual Symposium on March 12 and 13, 2010 in Miami Beach, Florida. If you would like more information about the symposium please feel free to contact us at mcisymposium@msmc.com
The Meeting
The purpose of this symposium is to provide a forum for new information and for in-depth discussions about advances in research, related to the clinical diagnosis, progression and treatment of Alzheimer's Disease. This symposium will emphasize the early stage of AD and the preclinical deficits that are associated with increased risk for subsequent dementia. We will examine recent developments in understanding risk factors which lay the groundwork for potential strategies for treating and delaying Alzheimer's disease. We will present results from several longitudinal and cross-sectional studies that have explored clinical, imaging and biomarkers factors that are related to AD.
The symposium will include two keynote addresses and four individually themed symposia, each featuring national experts in the fields of neurology, psychiatry, geriatrics, neuropsychology, radiology, epidemiology, genetics and pharmacology. Each mini-symposium will be followed by an extended discussion period, allowing active audience participation to promote a better understanding of the issues.
Educational Objectives
Upon completion of this symposium, the attendees should be able to:
- Describe the rationale for a preclinical AD diagnosis.
- Name preclinical factors that increase the risk for subsequent AD or dementia.
- Discuss the results of clinical drug studies and strategies to enrich prevention trials.
- Recognize the difference and similarities between amnestic and non-amnestic MCI.
- Understand the challenges in interpreting the results of psychometric tests in MCI and early AD.
|
|
| |
|
|
